COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Telomir Pharmaceuticals unveils new preclinical findings showing Telomir-1 reactivates tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models, offering potential for improved chemotherapy response and metastasis control -
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Telomir Pharmaceuticals announces Telomir-1's new in vitro results inhibiting KDM5 family, expanding epigenetic therapy possibilities in cancer treatment and aging slowdown -
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance
